Nitric oxide-releasing medical devices

Details Nitric oxide-releasing medical devices Nitric oxide-releasing medical devices

2008-09-16

2008-09-16

Barts, Samuel A (Department: 1621)

Prosthesis (i.e., artificial body members), parts thereof, or ai

Arterial prosthesis

Stent structure

Reexamination Certificate

active

10041200

ABSTRACT:
An implant or intravascular stent comprising a polymeric composition capable of releasing nitric oxide under physiological conditions. The polymeric composition comprises a polymer and at least one nitric oxide-releasing N2O2−functional group bound to the polymer.

REFERENCES:
patent: 3153094 (1964-10-01), Reilly
patent: 4265714 (1981-05-01), Nolan et al.
patent: 4482533 (1984-11-01), Keith
patent: 4638079 (1987-01-01), Inskip et al.
patent: 4708854 (1987-11-01), Grinstead
patent: 4921683 (1990-05-01), Bedell
patent: 4952289 (1990-08-01), Ciccone et al.
patent: 4954526 (1990-09-01), Keefer
patent: 4985471 (1991-01-01), Ohta et al.
patent: 5039705 (1991-08-01), Keefer et al.
patent: 5087631 (1992-02-01), Shaffer et al.
patent: 5087671 (1992-02-01), Loeppky et al.
patent: 5094815 (1992-03-01), Conboy et al.
patent: 5155137 (1992-10-01), Keefer et al.
patent: 5208233 (1993-05-01), Keefer et al.
patent: 5250550 (1993-10-01), Keefer et al.
patent: 5366997 (1994-11-01), Keefer et al.
patent: 5405919 (1995-04-01), Keefer et al.
patent: 5525357 (1996-06-01), Keefer et al.
patent: 5632981 (1997-05-01), Saavedra et al.
patent: 5691423 (1997-11-01), Smith et al.
patent: 5718892 (1998-02-01), Keefer et al.
patent: 211789 (1984-07-01), None
patent: 425154 (1990-10-01), None
patent: 469520 (1992-02-01), None
patent: WO 89/12627 (1989-12-01), None
Artysbasheva et al., “Synthesis of 1-Alkoxy-3,3-Dialkyltriazene 2-Oxides from Alkoxyamines and Nitrosoamines,” translated fromZhurnal Organicheskoi Khimii(Journal of Organic Chemistry-U.S.S.R.), 28, (6) 1168-1173 (1987).
Bonakdar et al., “Continuous-Flow Performance of Carbon Electrodes Modified With Immobilized Fe(II)/FE(III) Centers,”Calanta, 36, 219-225 (1989).
DeFeudis, “Endothelium-Dependent Vasorelaxation—A New Basis for Developing Cardiovascular Drugs,”Drugs of Today, 24 (2), 103-115 (1988).
DeLuca et al., “Parenteral Drug-Delivery Systems,” inPharmaceutica and Pharmacy Practice, Banker et al., eds., 238-250 (J. B. Lippincott Co., Philadelphia, PA) (1982).
Drago, “Reactions of Nitrogen(II) Oxide,” inFree Radicals in Organic Chemistry, Advances in Chemistry Series No. 36, 143-149 (American Chemical Society, Washington, DC) (1962).
Drago et al., “The Reaction of Nitrogen(II) Oxide with Various Primary and Secondary Amines,”J. Am. Chem. Soc., 83, 1819-1822 (1961).
Furchgott, “The Role of Endothelium in the Responses of Vascular Smooth Muscle to Drugs,”Ann. Rev. Pharmacol. Toxicol., 24, 175-97 (1984).
Garg et al., “Nitric Oxide-Generating Vasodilators Inhibit Mitogenesis and Proliferation of Balb/C 3T3 Fibroblasts by a Cyclic GMP-Independent Mechanism,”Biochem. and Biophys. Res. Comm., 171, 474-479 (1990).
Gehlen et al., “Uber Reaktionen und Eigenschafter des Stickoxyds und seiner Verbindungen (II.Mitteil): Zur Kenntnis der Salze der Stickoxyd-schwefligen Saure,”Berichte d. D. Chem. Gesellschaft, LXV, 1130-1140 (1932). (Reactions and properties of nitric oxide and its compounds. II. The salts of the nitric oxide compound of sulfurous acid, Chemical Abstracts, 26, 4764-65.).
Hansen et al., “N-Nitrosation of Secondary Amines by Nitric Oxide via the ‘Drago Complex’,” inN-Nitroso Compounds: Occurrence and Biological Effects, IARC Scientific Publications No. 41, 21-29 (International Agency for Research on Cancer, Lyon, France) (1982).
Hibbs et al., “Nitric Oxide: A Cytotoxic Activated Macrophage Effector Molecule,”Biochem. and Biophys. Res. Comm., 157, 87-94 (1988).
Holford et al., “Understanding the Dose-Effect Relationship: Clinical Application of Pharmacokinetic-Pharmacodynamic Models,”Clinical Pharmacokinetics, 6, 429-453 (1981).
Hrabie JA, Saavedra JE, Roller PP, Southan GJ, Keefer LK, “Conversion of proteins to diazeniumdiolate-based nitric oxide donors,”Bioconjugate Chem., 10 (5), 838-842 (Sep.-Oct. 1999).
Ignarro “Endothelium-derived nitric oxide: actions and properties,”The FASEB Journal, 3, 31-36 (1989).
Ignarro et al., “The Pharmacological and Physiological Role of Cyclic GMP in Vascular Smooth Muscle Relaxation,”Ann. Rev. Pharmacol. Toxicol., 25, 171-191 (1985).
Ignarro et al., “Mechanism of Vascular Smooth Muscle Relaxation by Organic Nitrates, Nitrites, Nitroprusside and Nitric Oxide: Evidence for the Involvement of S-Nitrosothiols as Active Intermediates,”J. Pharmacol. Exp. Ther., 218, 739-749 (1981).
Ignarro, “Nitric Oxide: A Novel Signal Transduction Mechanism for Transcellular Communication,”Hypertension, 16, 477-483 (1990).
Ignarro, “Biosynthesis and Metabolism of Endothelium-Derived Nitric Oxide,”Ann. Rev. Pharmacol. Toxicol., 30, 535-560 (1990).
Jones, “Metastable Polymers of the Nitrogen Oxides. 1. Open Chain Nitric Oxide Analogues of Polythlazyl: A MNDO/AMI Study,”J. Phys. Chem., 91, 2588-2595 (1991).
Jones, “Metastable Polymers of the Nitrogen Oxides. 2. Open-Chain Polymers of the Nitric Oxide Dimers and of Nitrous Oxide: A MNDO/AM1 Study,”J. Phys. Chem., 96, 594-603 (1992).
Kobayashi et al. Chem. Letters 11, 1181-1186.
Kruszyna et al., “Red Blood Cells Generate Nitric Oxide from Directly Acting, Nitrogenous Vasodilators,”Toxicol. Appl. Pharmacol., 91, 429-438 (1987).
Kuhn et al., “Endothelium-Dependent Vasodilation in Human Epicardial Coronary Arteries: Effect of Prolonged Exposure to Glycerol Trinitrate or SIN-1,”J. Cardiovasc. Pharmacol., 14 (Suppl. 11), S47-S54 (1989).
Longhi et al., “Metal-Containing Compounds of the Anion (C.sub.2 H.sub.5).sub.2NN.sub.2 O.sub.2,”Inorg. Chem., 2, 85-88 (1963).
Lundblad, “Techniques In Protein Modification,” 1995, CRC Press, Boca Raton, Florida.
Lutz et al., “Isolation of Trioxidinitrato(II) Complexes of Some First Row Transition Metal Ions,”J.C.S. Chem. Comm., 247 (1977).
Maragos et al., “Complexes of No with Nucleophiles as Agents for the Controlled Biological Release of Nitric Oxide. Vasorelaxant Effects,”J. Med. Chem., 34, 3242-3247 (1991).
Marletta et al., “Unraveling the Biological Significance of Nitric Oxide,”BioFactors, 2, 219-225 (1990).
Mascarenhas, Oscar C. “Epoxy-Baseed Medical Grade Adhesive Hydrogels and Nitric Oxide Releasing Polymers,” dissertation, University of Akron, pp. 56-62, 74-81, (Dec. 1993).
Middleton et al., “Further Studies on the Interaction of Nitric Oxide With Transition-Metal Alkyls,”J. Chem. Soc. Dalton, 1898-1905, (1981).
Mitchell et al. “Biologically Active Metal-Independent Superoxide Dismutase Mimics” (Biochemistry, 29 (11) 2802-2807 (Mar. 20, 1990).
Myers et al., “Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocystein than nitric oxide,”Nature, 345, 161-163 (1990).
Nakanishi et al., Participation of Hydrocarbons in the Photodimerization of 3, 4-Dicholorocinnamic Acid,J.C.S. Chem Comm(1977).
Palmer et al., “Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor,”Nature, 327, 324-327 (1987).
Park et al., “Controlled Protein Release from Polyethyleneimine-Coated Poly (L-lactic Acid)/Pluronic Blend Matrices,”Pharmaceut. Res., 9, 37-39 (1992).
Saavedra et al. “Pperazine as a Linker for Incorporating the Nitric Oxide-Releasing Diazeniumdiolate Group into other Biomedically Relevant Functional Molecules,”J. Organic Chem., 64 (14), 5124-5131 (Jul. 9, 1999).
Smith et al., “Nitroprusside: A Potpourri of Biologically Reactive Intermediates,” inAdvances in Experimental Medicine and Biology, 283, Biological Reactive Intermediates IV, (Witmer et al., eds.), 365-369 (Plenum Press, New York NY) (1991).
Smith et al., “Complex Contractile Patterns in Canine Colon Produced by Spontaneous Release of Nitric Oxide,”Gastroenterology, 102 (4) Part 2, A516 (1992).

Affiliated with

Also associated with

Rating

Nitric oxide-releasing medical devices does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nitric oxide-releasing medical devices, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitric oxide-releasing medical devices will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3930024